Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded access study data suggesting the investigational therapy may deliver clinically meaningful benefits for patients.
Speaking with Proactive, CEO Ivor Elrifi said the placebo-controlled study has fully enrolled 48 participants across several leading US institutions, including Harvard, Yale, Cornell, Johns Hopkins, UMass Buffalo and Thomas Jefferson.
GameStop Corp (NYSE:GME) is requesting the approval of its shareholders to significantly increase its authorized share capital to as many as 2.5 billion shares, up from about 450 million, according to a Securities and Exchange Commission filing released Thursday.
The company said the proposal is intended to enhance financial flexibility for potential strategic transactions, including a possible acquisition of eBay, as well as other capital-raising or corporate initiatives that may arise in the future.
IMAX Corp (NYSE:IMAX) is exploring a sale and has approached entertainment companies as potential buyers, the Wall Street Journal reported on Friday, sending shares of the premium cinema operator up 14.2%.
The process is early and may not lead to a deal, according to the report.
Snail Inc (NASDAQ:SNAL) told investors on Friday that it is continuing to expand its international game development network through partnerships with three Poland-based studios as part of its broader global growth strategy.
The company, through its subsidiary Wandering Wizard, highlighted its collaborations with Above The Desk, developer of Above the Snow; Donkey Crew, creator of Bellwright; and Frozen Way Games, which is developing Honeycomb: The World Beyond.
American Resources Corp (NASDAQ:AREC) announced that its affiliated minority company ReElement Technologies has formed a joint venture with South Korea’s POSCO International to develop an integrated rare earth refining and permanent magnet manufacturing operation in the United States.
The companies plan to invest about $200 million in the project, which is intended to establish a domestic supply chain spanning feedstock sourcing, separation, purification, and refining, and permanent magnet production. Final site selection is currently underway.
EnWave Corp (TSX-V:ENW, OTC:NWVCF, FRA:E4U) announced it has inked a technology evaluation and license option agreement with one of the world's largest multinational food companies.
The agreement calls for the partner to evaluate REV technology at commercial scale across a range of food categories it serves globally.
Shares in Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF), the clean energy technology group, jumped 17% to 779.3p on Friday after UBS raised its price target to 970p from 570p, citing a dramatic increase in expected royalty income from manufacturing partners.
The investment bank, which reiterated its buy rating, said it had increased its forecast for cumulative solid oxide fuel cell (SOFC) shipments by 60% to 1.8 gigawatts by 2030, delivering royalties of more than £100 million that year alone.
Arkle Resources PLC (AIM:ARK) shares moved up, rising 12% to 0.73p, after it told investors it has accelerated drilling at its Erongo uranium project in Namibia after Phase 1 geophysical work defined multiple targets across two mineralisation styles.
The AIM-listed explorer said the Eastern EPL 8995 paleochannel target is now drill-ready, with around 1,500 metres of reverse circulation drilling planned from June 2026, or at the earliest contractor availability.
Shares in Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF), the Horsham-based developer of solid oxide fuel cell and electrolyser technology, jumped 15% to 765.8p on Friday in the absence of any formal announcement from the company.
Bulletin board chatter pointed to a reported price target upgrade from UBS to 970p as the catalyst, though the note could not be immediately verified (Proactive will update on this later).
Creo Medical Group PLC (AIM:CREO, FRA:1RC, OTC:CMEOF), the medical device company specialising in minimally invasive surgical endoscopy, saw its shares jump 27% to 14.44p after announcing plans to sell its remaining 49% interest in Creo Medical Europe alongside a placing and full-year results.
The company has entered into a non-binding agreement to sell the stake to a vehicle owned by Luis Collantes, the division's chief executive, at an enterprise value in line with its carrying value at the end of 2025, with cash from the deal expected in full at completion.
Creo Medical Group PLC (AIM:CREO, FRA:1RC, OTC:CMEOF) announced plans to raise approximately £5.5 million through a placing as the medical device company moves to strengthen its balance sheet while pursuing the sale of its remaining stake in Creo Medical Europe.
The AIM-listed group said it intends to issue around 36.7 million new shares at 15p each, a 31.9% premium to Thursday’s closing mid-market price of 11.4p. The new shares would represent about 8.9% of Creo’s existing issued share capital. Certain directors have indicated they intend to subscribe for around £2.15 million of the placing, including £2 million from chair Kevin Crofton, £100,000 from finance chief Richard Rees and £50,000 from chief executive Craig Gulliford.
Zinc Media Group, the content and event production company, has agreed to buy William Martin Qatar, a Middle East creative agency, for an initial £400,000, paid entirely in new shares.
The maximum deal value could reach £1.12 million if WMP Qatar hits a series of earnings targets over the next two financial years.
A new research report on Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has highlighted the company’s expanding exposure to carbon capture and storage (CSS) infrastructure, arguing the opportunity could provide an earlier commercial pathway alongside its established hydrogen shipping strategy.
In a note released on Thursday, Longspur Research said the market had not fully appreciated the value of Provaris’ move into liquid CO2 storage and transport infrastructure, particularly as Europe accelerates development of carbon sequestration projects.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) earlier this week outlined progress on its developing hydrogen export supply chain after signing a cooperation agreement with K Line and Norwegian Hydrogen aimed at supplying hydrogen from Norway into Germany.
Speaking with Proactive, managing director and CEO Martin Carolan said the agreement formally brings together the production, shipping and future offtake components required to advance the project toward commercialisation.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort of its ongoing Phase 1b azer-cel trial ahead of a major presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The clinical-stage immuno-oncology company said its off-the-shelf allogeneic CAR T therapy delivered an overall response rate of 81% in evaluable patients across a range of relapsed or refractory blood cancers, including chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL).